Acurx Pharmaceuticals, Inc. — Form 8-K
Filed October 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 8/100
What the filing says
Acurx Pharmaceuticals filed an 8-K on October 16, 2026, reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). The filing does not disclose the specific voting matters, vote results, share counts, or dollar amounts in the text provided—only that such matters were submitted. No counterparties, dates of shareholder meetings, or material business changes are specified in this extract.
Why this rating
8-K Item 5.07 is routine disclosure; no material business impact disclosed. Company scale ($13.7M) makes even routine governance filings low-impact absent crisis detail.
Extracted items
See more from October 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.